

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

GUST H. BARDY,  
  
Plaintiff,  
  
v.  
  
CARDIAC SCIENCE CORP.,  
  
Defendant.

CASE NO. C13-0778JLR  
  
ORDER ON PARTIAL MOTION  
TO DISMISS

**I. INTRODUCTION**

Before the court is Defendant Cardiac Science Corporation’s (“CSC”) motion to dismiss the second cause of action in Plaintiff Dr. Gust H. Bardy’s third amended complaint. (*See* Mot. (Dkt. # 52).) CSC and Dr. Bardy collaborated for several years in researching and developing medical devices, but the relationship eventually soured. CSC and Dr. Bardy’s collaboration was governed by a contract and Dr. Bardy alleges that CSC breached that contract. (*See* 3d. Am. Compl. (Dkt. # 50).) CSC now moves to dismiss Dr. Bardy’s claim for breach of contract. Having considered the submissions of the

1 parties, the balance of the record, and the relevant law, and no party having requested oral  
2 argument, the court DENIES in part and GRANTS in part CSC’s motion to dismiss.

## 3 II. FACTS

4 Both Dr. Bardy and CSC work in the field of heart disease treatment. Dr. Bardy is  
5 a cardiologist who has experience designing devices to treat and manage irregular  
6 heartbeat conditions and diseases (also called “cardiac arrhythmias”). (3d Am. Compl.  
7 ¶ 2.) Dr. Bardy describes himself as an “entrepreneurial cardiologist” with experience  
8 designing and executing clinical trials for heartbeat-monitoring devices and conducting  
9 research, development, and commercialization for those devices and related software.

10 (*Id.*) CSC is a corporation that develops, manufactures, and markets heart-related  
11 medical devices such as automated external defibrillators, electrocardiograph devices,  
12 and similar devices. (*Id.* ¶ 3.)

13 Dr. Bardy and CSC signed an agreement to collaborate in December 2009 titled  
14 “Collaboration and Consulting Agreement” (hereinafter referred to as “the Agreement”).  
15 (*Id.* ¶ 8.) The purpose of the Agreement was to “form a collaboration and consulting  
16 agreement to design, develop, manufacture, commercialize, and use medical devices and  
17 diagnostic technologies.” (*Id.*) Under the Agreement, CSC would provide at least  
18 \$500,000.00 in funding, as well as office space, other resources, and an annual salary of  
19 \$175,000.00 to Dr. Bardy. (*Id.* ¶¶ 9, 10.) In return, Dr. Bardy would conduct research  
20 and attempt to develop medical devices that could be commercialized by CSC. (*Id.*)

21 The collaboration yielded a product called the “mySense Monitor.” (*Id.* ¶ 19.)  
22 The mySense Monitor is a wearable electrocardiograph monitor about the size of a large

1 band-aid. (*Id.*) It continuously monitors and records the electrical activity of the  
2 cardiovascular system and heart and transmits the data to its associated software for  
3 review and analysis. (*Id.*) Dr. Bardy designed and developed this product, which he  
4 claims “represents a significant clinical and cost improvement” over prior technology.  
5 (*Id.* ¶ 20.) He also obtained United States Food and Drug Administration (“FDA”)  
6 approval for the product. (*Id.* ¶ 21.)

7 The parties’ activities under the Agreement were termed the “Collaboration  
8 Program.” (*Id.* ¶ 8.) The Collaboration Program was coordinated by a Steering  
9 Committee consisting of Dr. Bardy and three CSC executive officers. (*Id.* ¶ 22.) The  
10 Steering Committee could act only upon the approval of Dr. Bardy and two of the three  
11 CSC executives. (Am. Compl. Ex. A (Dkt. # 29) (“Agreement”) ¶ 5.5.)<sup>1</sup> One of the  
12 Steering Committee’s main functions was to formulate and approve Collaboration Plans  
13 and Budgets. (*Id.*) Dr. Bardy and CSC agreed that:

14 Subject to the terms and conditions of this Agreement, the Parties will  
15 cooperate to perform the Collaboration Program in accordance with the  
16 Collaboration Plans and Budgets and other directions of the Steering  
17 Committee.

18 (*Id.* ¶ 5.2.) Dr. Bardy alleges that the parties “intended that the Collaboration Plans and  
19 Budgets be incorporated into and/or modify the Agreement.” (3d Am. Compl. ¶ 28.)

---

20 <sup>1</sup> The Agreement is properly before the court on this motion to dismiss because it is incorporated  
21 by reference into the third amended complaint. *See United States v. Ritchie*, 342 F.3d 903, 908 (9th Cir.  
22 2003) (“A court may, however, consider certain materials—documents attached to the complaint,  
documents incorporated by reference in the complaint, or matters of judicial notice—without converting  
the motion to dismiss into a motion for summary judgment.”).

1           The Collaboration Plan and Budget adopted for the 2012 calendar year allocated  
2 \$2.5 million to fund Dr. Bardy’s activities under the Agreement. (*Id.* ¶ 26.) Dr. Bardy  
3 alleges that, based on this and other Collaboration Plans and Budgets, he did not seek to  
4 exclude the mySense Monitor from the Collaboration Program as was his “right” under  
5 the Agreement. (*Id.* ¶ 29.)

6           Dr. Bardy does not provide copies of any Collaboration Plans and Budgets with  
7 his third amended complaint. (*See id.* ¶ 30.) Nonetheless, he alleges that CSC breached  
8 the obligations set forth in these plans in four ways: that CSC failed to pay the  
9 Collaboration’s main trial doctor working to support FDA approval of the mySense  
10 Monitor; that CSC failed to pay legal fees to an intellectual property law firm; that CSC  
11 failed to pay the contract manufacturer of the mySense monitor; and that CSC failed to  
12 assign an internal product manager to the mySense Monitor product. (*Id.* ¶ 32-35.)

13           On April 9, 2013, CSC sent Dr. Bardy a letter unilaterally terminating the  
14 Agreement. (*Id.* ¶ 40.) Pursuant to the Agreement, if CSC’s termination is not  
15 predicated on Dr. Bardy’s material breach of the Agreement, CSC must continue to pay  
16 Dr. Bardy monthly severance payments for one year. (Agreement ¶ 10; 3d. Am. Compl.  
17 ¶ 42.) Dr. Bardy alleges that, as of the date CSC terminated the Agreement, he had  
18 performed all of his material obligations under the Agreement. (3d. Am. Compl. ¶ 41.)  
19 He also alleges that CSC has not made any severance payments to him. (*Id.* ¶ 43.)

20           This court previously dismissed Dr. Bardy’s contract claim to the extent it was  
21 premised on the theory that the Agreement generally obligated CSC to make  
22 “commercially reasonable efforts” to develop and commercialize the mySense Monitor

1 and that CSC breached the Agreement by failing to undertake such efforts. (*See* 10/10/13  
2 Order (Dkt. # 43) at 5-10; *see also* Am. Order (Dkt. # 49).) Dr. Bardy amended his  
3 complaint to focus on the obligations allegedly created by the Collaboration Plans and  
4 Budgets. (*See generally* 3d Am. Compl.) CSC now moves to dismiss Dr. Bardy’s  
5 contract claim for the second time. (*See generally* Mot.)

### 6 III. ANALYSIS

#### 7 A. Motion to Dismiss Standard

8 Under Federal Rule of Civil Procedure 12(b)(6), a court must dismiss a complaint  
9 if it fails to state a claim upon which relief can be granted. Fed. R. Civ. P. 12(b)(6). In  
10 determining whether to grant a Rule 12(b)(6) motion, the court must accept as true all  
11 “well-pleaded factual allegations” in the complaint. *Ashcroft v. Iqbal*, 556 U.S. 662, 679  
12 (2009). Dismissal for failure to state a claim “is proper if there is a lack of a cognizable  
13 legal theory or the absence of sufficient facts alleged under a cognizable legal theory.”  
14 *Conservation Force v. Salazar*, 646 F.3d 1240, 1242 (9th Cir. 2011).

15 To survive a motion to dismiss, a complaint’s “[f]actual allegations must be  
16 enough to raise a right to relief above the speculative level.” *Bell Atl. Corp. v. Twombly*,  
17 550 U.S. 544, 555 (2007). The complaint must contain “sufficient factual matter,  
18 accepted as true, to state a claim to relief that is plausible on its face.” *Iqbal*, 556 U.S. at  
19 663 (internal quotation marks omitted); *see also Telesaurus VPC, LLC v. Power*, 623  
20 F.3d 998, 1003 (9th Cir. 2010). The court is not bound to accept as true labels,  
21 conclusions, formulaic recitations of the elements, or legal conclusions couched as  
22 factual allegations. *Twombly*, 550 U.S. at 555 (citing *Papasan v. Allain*, 478 U.S. 265,

1 286 (1986)). As the Supreme Court said in *Iqbal*, a complaint must do more than tender  
2 “‘naked assertions’ devoid of ‘further factual enhancement.’” *Iqbal*, 556 U.S. at 678  
3 (quoting *Twombly*, 550 U.S. at 557).

#### 4 **B. Collaboration Plan and Budgets**

5 Dr. Bardy claims that CSC breached both the terms of the original Agreement and  
6 additional obligations imposed by the Collaboration Plans and Budgets. In this section,  
7 the court addresses Dr. Bardy’s contract claim premised on the Collaboration Plan and  
8 Budgets.

##### 9 **1. Incorporation into the Agreement**

10 Dr. Bardy alleges that “[t]he parties intended that the Collaboration Plans and  
11 Budgets be incorporated into and/or modify the Agreement and impose additional,  
12 specific obligations on the Parties . . . .” (3d Am. Compl. ¶ 28.) The terms of the  
13 Agreement are consistent with Dr. Bardy’s allegation. For instance, the Agreement not  
14 only contemplates that the parties will adopt Collaboration Plans and Budgets—it  
15 requires it. (*See* Agreement ¶ 5.5 (“Within thirty (30) days after the Effective Date, the  
16 Steering Committee will meet to begin formulation of the initial Collaboration Plan and  
17 Budget, and within sixty (60) days . . . the Steering Committee will meet to review and  
18 approve the initial Collaboration Plan and Budget.”))

19 The Agreement also provides that both parties will act in accordance with the  
20 Collaboration Plans and Budgets, stating:

21 Subject to the terms and conditions of this Agreement, the Parties will  
22 cooperate to perform the Collaboration Program in accordance with the

1 Collaboration Plans and Budgets and other directions of the Steering  
2 Committee.

3 (*Id.* ¶ 5.2.) Additionally, the Agreement effectively incorporates the terms of future  
4 Collaboration Plans and Budgets into several of the Agreement’s provisions. (*See, e.g.,*  
5 *Id.* ¶ 3.1 (“Dr. Bardy will perform for CSC, as part of the Collaboration Program, such  
6 services as may be specified in the Collaboration Plans and Budgets . . . .”), ¶ 3.2 (“Dr.  
7 Bardy will . . . perform his services in accordance with any applicable schedule set forth  
8 in the Collaboration Plans and Budgets.”), ¶ 5.2(b) (“CSC will be responsible for  
9 providing resources for the Collaboration Program . . . as set forth in the applicable  
10 Collaboration Plans and Budgets.”).

11 Moreover, the Collaboration Plans and Budgets were created and adopted by the  
12 Steering Committee, which could only act with the approval of Dr. Bardy and two other  
13 CSC executive officers. (*Id.* ¶ 5.5). As such, the Collaboration Plans and Budgets  
14 represent further agreements by the parties. Taking into account the foregoing terms of  
15 the Agreement, Dr. Bardy has plausibly alleged that the parties intended to incorporate  
16 the Collaboration Plans and Budgets into their Agreement.<sup>2</sup>

---

17  
18  
19  
20 <sup>2</sup> CSC argues that Dr. Bardy’s claim fails because he has not shown that the Collaboration Plans  
21 and Budgets modified the parties’ original Agreement. (Mot. at 4.) It is well-established that contract  
22 modification requires consideration separate from that of the original contract. *Wagner v. Wagner*, 621  
P.2d 1279, 1284 (Wash. 1980). CSC contends that Dr. Bardy has not shown additional consideration.  
(Mot. at 4, Reply (Dkt. # 55) at 6-7.) However, because the court finds that Dr. Bardy has plausibly  
alleged the alternative theory that the Collaboration Plan and Budgets were incorporated into the  
Agreement, the court need not reach the issue of modification.

1           **2. Duty to Commercialize the mySense Monitor**

2           Dr. Bardy once again raises—and the court once again rejects—the theory that  
3 CSC had a general, overarching duty to develop and commercialize the mySense  
4 Monitor. (*See* Resp. (Dkt. # 54) at 5-6; 10/10/13 Order at 5-10; Am. Order.) Although  
5 the third amended complaint does not directly allege this theory, Dr. Bardy nonetheless  
6 argues in his response brief that “through the Collaboration Plans and Budgets, CSC  
7 affirmatively assumed a duty—to fund the development and commercialization of the  
8 mySense Monitor—that it has previously disavowed.” (Resp. at 5.) Dr. Bardy is  
9 incorrect.

10           This court already held that this theory is expressly precluded by the terms of the  
11 Agreement. (*See* 10/10/13 Order at 6; Am. Order.) There is no doubt that the Agreement  
12 eliminates any obligation on CSC’s behalf to develop and commercialize products arising  
13 out of the Collaboration Program when it says: “CSC will not have any obligation to,  
14 and will not have any liability on account of any delay or failure to, Develop,  
15 manufacture, market, or commercialize any Collaboration Products.” (Agreement  
16 ¶ 5.12.) Rather than establishing an affirmative duty to commercialize products, the  
17 Agreement provides that the “[d]evelopment, manufacture, marketing, and  
18 commercialization of Collaboration Products . . . will be guided and undertaken by CSC  
19 in its sole discretion.” (Agreement ¶ 5.12.)

20           Dr. Bardy identifies only four additional obligations allegedly imposed by the  
21 Collaboration Plans and Budgets: paying a trial doctor, retaining an intellectual property  
22 law firm, paying a contract manufacturer, and assigning a product manager. (Compl.



¶ 32-35.) Dr. Bardy also identifies an increased budget allocating \$2.5 million towards Dr. Bardy’s activities under the Agreement. (*Id.* ¶ 26.) However, merely increasing the funding and resource support for Dr. Bardy’s activities in no way vitiates or overrides Section 5.12’s express disclaimer of an overarching duty to commercialize products. After all, Section 5.12’s disclaimer coexisted peacefully with the original Agreement’s funding and resources provisions. (*See, e.g.*, Agreement ¶ 4.1 (guaranteeing funding of at least \$500,000.00 per year and two full-time employees).)

Dr. Bardy provides no sound reason why the funding provisions in the Collaboration Plans and Budgets create a duty to commercialize the mySense Monitor that effectively nullifies Section 5.12. To the contrary, a contract should be interpreted as a whole such that every term in the contract is given effect and force. *Boeing Co. v. Aetna Cas. & Sur. Co.*, 784 P.2d 507, 511 (Wash. 1990) (en banc). Interpretations that contradict and thereby nullify clauses within the contract are disfavored. *See Stouffer & Knight v. Cont’l Cas. Co.*, 982 P.2d 105, 110 (Wash. Ct. App. 1999). Section 5.2 of the Agreement states that the parties’ cooperation in accordance with the Collaboration Plans and Budgets remains “[s]ubject to the terms and conditions of [the] Agreement.” (Agreement ¶ 5.2.) Thus, interpreting the Agreement as a whole, any additional funding or resource commitments in the Collaboration Plan and Budgets remain subject to the terms of the original Agreement, including Section 5.12’s preclusion of an obligation to commercialize any products. Accordingly, the court dismisses Dr. Bardy’s contract claim that CSC owes a general duty to commercialize and develop the mySense Monitor. Because this is the second time the court has dismissed this claim and Dr. Bardy has

1 raised no new arguments, the claim is dismissed without leave to amend. *See Cook,*  
2 *Perkiss & Liehe v. N. Cal. Collection Serv.*, 911 F.2d 242, 247 (9th Cir. 1990).

### 3 **3. Damages**

4 It remains possible for Dr. Bardy to maintain a claim for breach of the specific  
5 terms and provisions expressly included in the Collaboration Plans and Budgets. Such a  
6 claim ultimately founders, however, on Dr. Bardy's failure to allege damages. As Dr.  
7 Bardy concedes, damages are an essential element of a breach of contract claim. *See*  
8 *Crabtree v. Bowers*, No. 45043-3-I, 102 Wash. App. 1017 at \*1 (Wash. Ct. App. 2000);  
9 (Resp. at 6 n.13). And yet, Dr. Bardy devotes only one sentence of his third amended  
10 complaint to damages, stating simply: "Dr. Bardy has suffered damages as a result of  
11 CSC's breach of the Agreement and of its obligations agreed to between the Parties and  
12 as set forth in the Collaboration Plans and Budgets." (3d Am. Compl. ¶ 71.) But the  
13 court is not bound to accept as true mere conclusions or formulaic recitations of the  
14 elements of a claim. *Twombly*, 550 U.S. at 555 (citing *Papasan*, 478 U.S. at 286).  
15 Rather, a complaint must do more than tender "'naked assertions' devoid of 'further  
16 factual enhancement.'" *Iqbal*, 556 U.S. at 678 (quoting *Twombly*, 550 U.S. at 557).  
17 Here, Dr. Bardy's naked assertion that the alleged breach of contract has damaged him is  
18 inadequate to survive a motion to dismiss.

19 Dr. Bardy in his response brief offers two theories of damages relevant to this  
20 claim, both of which are insufficient. First, Dr. Bardy argues that he is entitled to lost  
21 profits that he would have accrued absent CSC's alleged breach. (Resp. at 6.) Dr. Bardy  
22 identifies two ways in which he could have been compensated for the commercialization

1 of the mySense Monitor: milestone payments and royalties. (*Id.* at 6 n.14.) Specifically,  
2 under the Agreement, Dr. Bardy would receive a milestone payment if yearly revenue  
3 from a collaboration product sold by CSC reached a certain threshold; the amount of the  
4 payment would depend on the level of revenue reached. (Agreement ¶ 7.1.) In addition,  
5 Dr. Bardy would also earn a “percentage of the net consideration” received by CSC for  
6 the sale or licensing of all other collaboration technology and intellectual property. (*Id.*  
7 ¶ 7.2.)

8 The Agreement, however, also contains a limitation of liability that explicitly  
9 precludes recovery of lost profits:

10 Neither party will be liable to the other with respect to the subject matter of  
11 this agreement for any incidental, indirect, consequential, special, or  
12 punitive damages, or lost profits . . . regardless of whether any such claim  
for damages, lost profits, or other costs is based on tort, warranty, contract  
or any other legal theory . . . .”

13 (*Id.* ¶ 11.3). As such, Dr. Bardy’s damages claim for royalties, which constitutes a  
14 paradigmatic example of lost profits, is barred. The court notes that the milestone  
15 payments arguably do not fall under the traditional definition of lost profits. After all, Dr.  
16 Bardy is not seeking profits from the sale of the products themselves but rather lump sum  
17 payments hard-coded into the terms of the Agreement. Even so, Dr. Bardy’s complaint  
18 fails to adequately allege these damages.

19 Specifically, the complaint does not state a plausible claim that but for the  
20 commitments CSC allegedly breached—namely, paying a trial doctor, intellectual  
21 property law firm, and contract manufacturer and appointing a product manager—Dr.  
22 Bardy would have received milestone payments due to sales of the mySense Monitor.

1 | *See Larsen v. Walton Plywood Co.*, 390 P.2d 677, 686 (Wash. 1964) (stating that  
2 | damages are only recoverable if they are “the proximate result of a breach”). There is no  
3 | indication that these four commitments (or other unidentified obligations in the  
4 | Collaboration Plans and Budgets) were sufficient to achieve commercialization of the  
5 | mySense Monitor. And CSC had no affirmative duty to continue commercializing the  
6 | mySense Monitor beyond the obligations found in the Collaboration Plans. Even  
7 | assuming that the mySense Monitor was eventually fully commercialized, there is no  
8 | indication that sales would have reached the revenue levels necessary to earn Dr. Bardy a  
9 | milestone payment.

10 |         Damages must be established with reasonable certainty; speculative, uncertain,  
11 | and conjectural damages are not recoverable. *Tiegs v. Watts*, 954 P.2d 877, 886 (1998);  
12 | *see also Layman v. Swanson*, 3 Wash. 2d 370, 379, 101 P.2d 304, 308 (1940). Here, Dr.  
13 | Bardy makes no direct allegations of lost earnings and the inferences that can be drawn  
14 | from his complaint do not rise above conjecture. Conjecture, however, is not enough: to  
15 | survive a motion to dismiss, a complaint’s “[f]actual allegations must be enough to raise  
16 | a right to relief above the speculative level.” *Twombly*, 550 U.S. at 555. This is a level  
17 | which Dr. Bardy’s complaint fails to reach.

18 |         Dr. Bardy’s second theory of damages is that CSC’s failure to pay various vendors  
19 | harmed Dr. Bardy’s “reputation, relationship, and standing with the network of  
20 | contractors and suppliers who support him in his entrepreneurial efforts.” (Resp. at 6.)  
21 | As discussed above, the Agreement expressly precludes liability for consequential  
22 | damages. (*See* Agreement ¶ 11.3). Consequential damages are “losses that do not flow

1 | directly and immediately from an injurious act, but that result indirectly from the act.”  
2 | *Park Ave. Condo. Owners Ass’n v. Buchan Developments, L.L.C.*, 71 P.3d 692, 701  
3 | (Wash. Ct. App. 2003) (quoting Black's Law Dictionary 394 (7th Ed.1999)). Dr.  
4 | Bardy’s claim of reputational harm falls neatly within the definition of consequential  
5 | damages, and therefore is barred.<sup>3</sup> Even if this theory were not barred by the  
6 | Agreement’s limitation of liability provision, Dr. Bardy’s third amended complaint is  
7 | devoid of allegations supporting the theory. (*See* 3d. Am. Compl. ¶ 51 (alleging only that  
8 | Dr. Bardy introduced contractors and suppliers from his entrepreneurial “network” to  
9 | CSC).)

10 |       Therefore, Dr. Bardy’s contract claim for breach of the specific provisions of the  
11 | Collaboration Plans and Budgets is dismissed for a failure to plead damages. Because it  
12 | is possible that Dr. Bardy may be able to cure these deficiencies by alleging additional  
13 | facts, the court grants Dr. Bardy leave to amend the complaint within ten days of the date  
14 | of this order. *See Cook*, 911 F.2d at 247. Leave to amend is granted with respect to this  
15 | contract theory only.

### 16 | **C. Severance Payments**

17 |       Last, the court turns to Dr. Bardy’s claim for breach of contract based on CSC’s  
18 | failure to make severance payments. The Agreement provides that CSC may terminate  
19 | the Collaboration Program “(i) at any time on or after the first anniversary of the  
20 | Effective Date [December 6, 2010], or (ii) in the event that Dr. Bardy breaches any of his

---

21 |  
22 | <sup>3</sup> The court notes that Dr. Bardy’s claim for lost milestone payments also meets this definition of consequential damages. For this reason also, Dr. Bardy fails to adequately allege damages.

1 material obligations under this Agreement and fails to cure the material breach within  
2 ninety (90) days . . . .” (Agreement ¶ 10.2; 3d. Am. Compl. ¶ 11). If CSC terminates the  
3 Agreement early and Dr. Bardy is not in material breach:

4       CSC will continue to pay Dr. Bardy the monthly installments of the  
5 consulting consideration under Section 3.2 [sic] for a period commencing  
6 with the first day after the last day of the Term and ending upon the later of  
7 (i) the fourth (4th) anniversary of the Effective Date or (ii) twelve (12)  
8 months after the end of the Term.

9 (Agreement ¶ 10.3(b); 3d. Am. Compl. ¶ 12.) Dr. Bardy’s consulting consideration was  
10 an annual cash retainer of \$175,000.00. (Agreement ¶ 3.3; 3d. Am. Compl. ¶ 10.)

11       Dr. Bardy alleges that CSC sent Dr. Bardy a letter unilaterally terminating the  
12 Agreement on April 09, 2013. (3d. Am. Compl. ¶ 40.) Dr. Bardy also alleges that, as of  
13 the termination date, Dr. Bardy had performed all of his material obligations under the  
14 Agreement. (*Id.* ¶ 41.) According to the terms of the Agreement, CSC was required to  
15 continue to pay Dr. Bardy severance payments for the next twelve months in the total  
16 amount of \$175,000.00. (*Id.* ¶ 42.) But Dr. Bardy also alleges that CSC has not made  
17 any severance payments to Dr. Bardy. (*Id.* ¶ 43.) Therefore, Dr. Bardy has alleged all  
18 elements of a breach of contract claim. *Lehrer v. State Dep’t of Soc. & Health Servs.*, 5  
19 P.3d 722, 727 (Wash. Ct. App. 2000) (“Generally, a plaintiff in a contract action must  
20 prove a valid contract between the parties, breach, and resulting damage.”) Accordingly,  
21 CSC’s motion to dismiss Dr. Bardy’s contract claim based on the Agreement is denied.  
22

20 //


21 //

22

1 **IV. CONCLUSION**

2 For the foregoing reasons, the court GRANTS in part and DENIES in part CSC's  
3 motion to dismiss (Dkt. # 52). Dr. Bardy is granted partial leave to amend within 10 days  
4 of the date of this order.

5 Dated this 26th day of January, 2014.

6 

7  
8 JAMES L. ROBART  
United States District Judge

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22